Waiting for the changes after the adoption of steatotic liver disease
2
조회
0
다운로드
14
인용
0
참고문헌
키워드
초록
Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term “steatosis” instead of “fatty”. Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.
Abstract
Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term “steatosis” instead of “fatty”. Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.
참고문헌 (19)
- Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol (2023)[DOI]
- Eslam M, "MAFLD : A consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
- Eileen Laurel Yoon, "Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology", Clinical and Molecular Hepatology, 29(2), pp.371~373 (2023), 대한간학회
- Yu Jun Wong, "Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis", Clinical and Molecular Hepatology, 29(3), pp.705~720 (2023), 대한간학회
- Yang M, "Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia", Liver Int, 42, pp.1981~1990 (2022)
- Kim MN, "Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver", Aliment Pharmacol Ther, 55, pp.97~107 (2022)
- Lee YB, "Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B", Hepatology, 73, pp.2266~2277 (2021)
- Carol M, "Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life", PLoS One, 17, pp.e0265153~ (2022)
- Younossi Z, "Stigma in NAFLD and NASH : a global survey of patients and providers", J Hepatol, 78, pp.S627~S628 (2023)
- Shiha G, "MAFLD 2022 : An ELPA", ALPA, J Hepatol, pp.2022, 77[DOI]
- Karlsen TH, "The EASL-Lancet Liver Commission : protecting the next generation of Europeans against liver disease complications and premature mortality", Lancet, 399, pp.61~116 (2022)
- Park H, "Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era", Hepatol Res, 52, pp.247~254 (2022)
- Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol (2023)[DOI]
- Saisai Zhang, "Screening strategy for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.103~122 (2023), 대한간학회
- Graupera I, "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population", Clin Gastroenterol Hepatol, 20, pp.2567~2576 (2022)
- Silvia Sookoian, "Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response", Clinical and Molecular Hepatology, 29, pp.184~195 (2023), 대한간학회
- Sae Kyung Joo, "Interaction between sarcopenia and nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.68~78 (2023), 대한간학회
- Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
- Eunji Ko, "Risk factors in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.79~85 (2023), 대한간학회